Results

Total Results: 1,175 records

Showing results for "fentanyl".

121. Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/studies/index.html?page=310
     January 01, 2024 - This study describes patterns and perceptions of fentanyl exposure among opioid users in Rhode Island … It concluded that among illicit opioid users in Rhode Island, known or suspected fentanyl exposure is … common, yet demand for fentanyl is low. … Fentanyl-contaminated drugs are generating user interest in effective risk mitigation strategies, including … Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island

122. Using ventilator splitters during the COVID-19 pandemic--letter to health care providers. | PSNet
     psnet.ahrq.gov/issue/using-ventilator-splitters-during-covid-19-pandemic-letter-health-care-providers
     February 15, 2024 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … March 3, 2010 Accidental exposures to fentanyl patches continue to be deadly to children … December 10, 2008 Fentanyl transdermal system (marketed as Duragesic) information.

123. Hospira issues a voluntary nationwide recall for one lot of 0.5% Bupivacaine Hydrochloride Injection, USP and one lot of 1% Lidocaine HCl Injection, USP due to mislabeling. | PSNet
     psnet.ahrq.gov/issue/hospira-issues-voluntary-nationwide-recall-one-lot-05-bupivacaine-hydrochloride-injection-usp
     May 15, 2013 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … May 25, 2022 Accidental exposures to fentanyl patches continue to be deadly to children … July 21, 2021 Fentanyl transdermal system (marketed as Duragesic) information.

124. FDA advises health care professionals and patients about insulin pen packaging and dispensing. | PSNet
     psnet.ahrq.gov/issue/fda-advises-health-care-professionals-and-patients-about-insulin-pen-packaging-and-dispensing
     June 22, 2011 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … December 23, 2020 Fentanyl transdermal system (marketed as Duragesic) information. … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

125. Wear face masks with no metal during MRI exams. | PSNet
     psnet.ahrq.gov/issue/wear-face-masks-no-metal-during-mri-exams
     June 22, 2011 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … February 24, 2022 - February 24, 2022 Fentanyl transdermal system (marketed as Duragesic … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

126. Morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL): medication use error—reports of accidental overdose. | PSNet
     psnet.ahrq.gov/issue/morphine-sulfate-oral-solution-100-mg-5-ml-20-mgml-medication-use-error-reports-accidental
     June 22, 2011 - October 7, 2009 FDA requiring color changes to Duragesic (fentanyl) pain patches to aid … November 13, 2013 Fentanyl transdermal system (marketed as Duragesic) information. … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

127. A Review of FDA’s Approach to Medical Product Shortages. | PSNet
     psnet.ahrq.gov/issue/review-fdas-approach-medical-product-shortages
     June 22, 2011 - October 7, 2009 FDA requiring color changes to Duragesic (fentanyl) pain patches to aid … March 3, 2010 Accidental exposures to fentanyl patches continue to be deadly to children … December 10, 2008 Fentanyl transdermal system (marketed as Duragesic) information.

128. Potentially fatal errors with GDH-PQQ [glucose dehydrogenase pyrroloquinoline quinone] glucose monitoring technology. | PSNet
     psnet.ahrq.gov/issue/potentially-fatal-errors-gdh-pqq-glucose-dehydrogenase-pyrroloquinoline-quinone-glucose
     June 22, 2011 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … February 24, 2022 - February 24, 2022 Fentanyl transdermal system (marketed as Duragesic … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

129. Infections associated with reprocessed flexible bronchoscopes. | PSNet
     psnet.ahrq.gov/issue/infections-associated-reprocessed-flexible-bronchoscopes
     March 11, 2015 - October 7, 2009 FDA requiring color changes to Duragesic (fentanyl) pain patches to aid … December 10, 2008 Fentanyl transdermal system (marketed as Duragesic) information. … August 5, 2015 Accidental exposures to fentanyl patches continue to be deadly to children

130. Tamiflu (oseltamivir) for oral suspension: potential medication errors. | PSNet
     psnet.ahrq.gov/issue/tamiflu-oseltamivir-oral-suspension-potential-medication-errors
     October 21, 2009 - October 19, 2022 FDA requiring color changes to Duragesic (fentanyl) pain patches to … October 3, 2022 Fentanyl transdermal system (marketed as Duragesic) information. … August 5, 2015 Accidental exposures to fentanyl patches continue to be deadly to children

131. FDA Safety Communication: flexible bronchoscopes and updated recommendations for reprocessing. | PSNet
     psnet.ahrq.gov/issue/fda-safety-communication-flexible-bronchoscopes-and-updated-recommendations-reprocessing
     March 11, 2015 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … July 26, 2006 Accidental exposures to fentanyl patches continue to be deadly to children … December 10, 2008 Fentanyl transdermal system (marketed as Duragesic) information.

132. Luer Connector Misconnections: Under-Recognized but Potentially Dangerous Events. | PSNet
     psnet.ahrq.gov/issue/luer-connector-misconnections-under-recognized-potentially-dangerous-events
     November 19, 2008 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children … December 10, 2008 Fentanyl transdermal system (marketed as Duragesic) information.

133. Kadcyla (ado-trastuzumab emtansine): drug safety communication—potential medication errors resulting from name confusion. | PSNet
     psnet.ahrq.gov/issue/kadcyla-ado-trastuzumab-emtansine-drug-safety-communication-potential-medication-errors
     October 09, 2013 - Related Resources From the Same Author(s) FDA requiring color changes to Duragesic … (fentanyl) pain patches to aid safety―emphasizing that accidental exposure to used patches can cause … May 25, 2022 Fentanyl transdermal system (marketed as Duragesic) information. … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

134. FDA Guidance Document: Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment. | PSNet
     psnet.ahrq.gov/issue/fda-guidance-document-hospital-bed-system-dimensional-and-assessment-guidance-reduce
     March 22, 2006 - March 3, 2010 Accidental exposures to fentanyl patches continue to be deadly to children … January 13, 2016 Fentanyl transdermal system (marketed as Duragesic) information. … November 13, 2013 FDA requiring color changes to Duragesic (fentanyl) pain patches to

135. Relenza (zanamivir) inhalation powder. | PSNet
     psnet.ahrq.gov/issue/relenza-zanamivir-inhalation-powder
     October 21, 2009 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … August 5, 2015 Fentanyl transdermal system (marketed as Duragesic) information. … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

136. Promethazine HCl (marketed as Phenergan) Information. | PSNet
     psnet.ahrq.gov/issue/promethazine-hcl-marketed-phenergan-information
     February 22, 2006 - November 13, 2013 FDA requiring color changes to Duragesic (fentanyl) pain patches to … February 20, 2013 Accidental exposures to fentanyl patches continue to be deadly to children … August 5, 2015 Fentanyl transdermal system (marketed as Duragesic) information.

137. FDA alerts health care professionals to the temporary absence of warning statement on the vial caps of two neuromuscular blocking agents. | PSNet
     psnet.ahrq.gov/issue/fda-alerts-health-care-professionals-temporary-absence-warning-statement-vial-caps-two
     June 22, 2011 - January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … December 23, 2020 Fentanyl transdermal system (marketed as Duragesic) information. … October 3, 2022 Accidental exposures to fentanyl patches continue to be deadly to children

138. Preventing vincristine administration errors. | PSNet
     psnet.ahrq.gov/issue/preventing-vincristine-administration-errors
     April 26, 2023 - November 9, 2016 Fentanyl transdermal system (marketed as Duragesic) information.

139. Safety Considerations for Product Design to Minimize Medication Errors: Guidance for Industry. | PSNet
     psnet.ahrq.gov/issue/safety-considerations-product-design-minimize-medication-errors-guidance-industry
     January 13, 2021 - March 3, 2010 Accidental exposures to fentanyl patches continue to be deadly to children … January 19, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … September 29, 2021 Accidental exposures to fentanyl patches continue to be deadly to

140. FDA public health notification: unretrieved device fragments. | PSNet
     psnet.ahrq.gov/issue/fda-public-health-notification-unretrieved-device-fragments
     June 02, 2021 - February 16, 2011 FDA requiring color changes to Duragesic (fentanyl) pain patches to … March 3, 2010 Accidental exposures to fentanyl patches continue to be deadly to children … August 20, 2021 Accidental exposures to fentanyl patches continue to be deadly to children